RTOG: Mitomycin-5-FU-Radiotherapy Confirmed as Anal Cancer Choice
17th Jul 2006, 06:25 GMT
TORONTO — A chemoradiotherapy regimen containing Platinol (cisplatin) and 5-FU (fluorouracil) carcinoma was not associated in a phase III trial for anal canal cancer with a better survival.
RTOG: Mitomycin-5-FU-Radiotherapy Confirmed as Anal Cancer Choice related news:
- RTOG: Gemzar Fails to Show Survival Benefit in Advanced Pancreatic Cancer — MedPage Today Gastroenterology
- RTOG: Targeted Therapies Work Best as Cancer Team Players — MedPage Today Radiology
- Welcome New Treatment For Head And Neck Cancer Patients In Scotland, Says Cancerbackup — Health News from Medical News Today
- Scottish Hospital to Offer Cancer Patients Advanced Radiotherapy Treatments With New Equipment and Software from Varian Medical Systems — PR Newswire: All Releases
- New Indication For Breast Cancer Drug, Arimidex™, Offers New Treatment Choice For Tamoxifen Patients In Europe — Health News from Medical News Today
- Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist — Cancer Gene Therapy
- Freedom to choose won't make you happier — EurekAlert! - Business and Economics
- 2006 World Cancer Declaration Calls For Global Commitment To Make Cancer Control Top Social And Political Priority — Health News from Medical News Today
- Women in United States still uninformed about lung cancer — The Cancer Blog
- Kylie's message of hope to cancer sufferers — the Mail online | TV & showbiz